Celltrion Healthcare Canada Limited announced yesterday that Health Canada granted a notice of compliance for Remsima SC®, an infliximab biosimilar of J& J’s Remicade®, for the treatment of adult patients with rheumatoid arthritis. Celltrion Senior Vice President Jovan Antunovic said the company is “delighted to bring the first subcutaneous form…